Capricor Therapeutics Inc (NASDAQ:CAPR)’s traded shares stood at 1.3 million during the last session, with the company’s beta value hitting 0.86. At the close of trading, the stock’s price was $12.74, to imply an increase of 0.31% or $0.04 in intraday trading. The CAPR share’s 52-week high remains $23.40, putting it -83.67% down since that peak but still an impressive 72.37% since price per share fell to its 52-week low of $3.52. The company has a valuation of $581.93M, with an average of 1.44 million shares in intraday trading volume over the past 10 days and average of 1.38 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Capricor Therapeutics Inc (CAPR), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give CAPR a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.32.
Capricor Therapeutics Inc (NASDAQ:CAPR) trade information
After registering a 0.31% upside in the last session, Capricor Therapeutics Inc (CAPR) has traded red over the past five days. The 5-day price performance for the stock is -4.07%, and 34.46% over 30 days. With these gigs, the year-to-date price performance is -7.68%. Short interest in Capricor Therapeutics Inc (NASDAQ:CAPR) saw shorts transact 10.67 million shares and set a 7.01 days time to cover.
The extremes give us $10 and $21.5 for target low and target high price respectively. As such, CAPR has been trading -68.76% off suggested target high and 21.51% from its likely low.
Capricor Therapeutics Inc (CAPR) estimates and forecasts
The rating firms project that company’s revenue will grow 184.04% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 3.16M. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 4.05M.Earnings reports from the last fiscal year show that sales brought in 4.91M and 3.97M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -35.63% before jumping 1.89% in the following quarter.
CAPR Dividends
Capricor Therapeutics Inc has its next earnings report out on 2025-Mar-18. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Capricor Therapeutics Inc (NASDAQ:CAPR)’s Major holders
Capricor Therapeutics Inc insiders hold 16.81% of total outstanding shares, with institutional holders owning 38.67% of the shares at 46.48% float percentage. In total, 38.67% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 1.63 million shares (or 5.1145% of shares), all amounting to roughly $7.77 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 1.55 million shares, or about 4.8645% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $7.39 million.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF as the top two Mutual Funds with the largest holdings of the Capricor Therapeutics Inc (CAPR) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 1.13 shares. This is just over 2.48% of the total shares, with a market valuation of $14.43 million. Data from the same date shows that the other fund manager holds a little less at 1.01, or 2.21% of the shares, all valued at about 12.83 million.
